Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.

MLA

Coughlan, J. J., et al. “Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.” JAMA Cardiology, vol. 6, no. 10, Oct. 2021, pp. 1121–29. EBSCOhost, https://doi.org/10.1001/jamacardio.2021.2228.

APA

Coughlan, J. J., Aytekin, A., Lahu, S., Ndrepepa, G., Menichelli, M., Mayer, K., Wöhrle, J., Bernlochner, I., Gewalt, S., Witzenbichler, B., Hochholzer, W., Sibbing, D., Cassese, S., Angiolillo, D. J., Hemetsberger, R., Valina, C., Müller, A., Kufner, S., Liebetrau, C., & Xhepa, E. (2021). Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. JAMA Cardiology, 6(10), 1121–1129. https://doi.org/10.1001/jamacardio.2021.2228

Chicago

Coughlan, J. J., Alp Aytekin, Shqipdona Lahu, Gjin Ndrepepa, Maurizio Menichelli, Katharina Mayer, Jochen Wöhrle, et al. 2021. “Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.” JAMA Cardiology 6 (10): 1121–29. doi:10.1001/jamacardio.2021.2228.